Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder

References

• Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2006;25:293
   PubMed Web of Science ®Google Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6(11 Suppl):S574-579
   PubMed Web of Science ®Google Scholar
• Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? J Am Geriatr Soc 2000;48:721-725
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-1315
   PubMed Web of Science ®Google Scholar
• Herschorn S, Gajewski J, Schulz J, et al. A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey. BJU Int 2007;101:52-58
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-336
   PubMed Web of Science ®Google Scholar
• Hu T-W, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003;61:1123-1128
   PubMed Web of Science ®Google Scholar
• Andersson K-E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53
   PubMed Web of Science ®Google Scholar
• Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005;25:511-519
   PubMed Web of Science ®Google Scholar
• Wagg AS, Fahey A, Siddiqui E. Persistence with oral antimuscarinics used for the treatment of overactive bladder in different age groups of patients in general practice. British Geriatrics Society, Autumn Meeting, October 7-9, 2009, Harrogate, UK, Abstr 95
   Google Scholar
• Siddiqui E, Fahey A, Huang M. Persistence with antimuscarinics in patients with overactive bladder syndrome: analysis of a UK database. 30th Congress of the Société Internationale d'Urologie (SIU), November 1–5, 2009, Shanghai, China, Abstr MP-17.10
   Google Scholar
• Blok B, van Kerrebroeck P, Buijs S, et al. Persistence with antimuscarinics in a European study of patients with overactive bladder syndrome. Int Urogynecol J 2009;20(Suppl 2):S192-193, Abstr 141
   Google Scholar
• Herschorn S, Stothers L, Carlson K, et al. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol 2010;183:1892-1898
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jönsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn 1998;17:599-611
   PubMed Web of Science ®Google Scholar
• Speakman M, Khullar V, Mundy A, et al. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008;24:2173-2179
   PubMed Web of Science ®Google Scholar
• Johannesson M, O'Conor RM, Kobelt-Nguyen G, et al. Willingness to pay for reduced urinary incontinence symptoms. Br J Urol 1997;80:557-562
   PubMedGoogle Scholar
• Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-310
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-1924
   PubMed Web of Science ®Google Scholar
• OPDP. Ontario Drug Benefit Formulary/Comparative Drug Index, 2009. www.health.gov.on.ca (accessed February 2009)
   Google Scholar
• Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-481
   PubMed Web of Science ®Google Scholar
• Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999;161:1809-1812
   PubMed Web of Science ®Google Scholar
• Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000;95:718-721
   PubMed Web of Science ®Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-470
   PubMed Web of Science ®Google Scholar
• Cardozo L, Heßdörfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008;102:1120-1127
   PubMed Web of Science ®Google Scholar
• Karram MM, Toglia MR, Serels SR, et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo controlled trial. Urology 2009;73:14-18
   PubMed Web of Science ®Google Scholar
• Hakkaart L, Verboom P, Phillips R, et al. The cost utility of solifenacin in the treatment of overactive bladder. Int Urol Nephrol 2008;41:293-298
   PubMed Web of Science ®Google Scholar